Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Do Genomic Testing Cancer Risk Results Alter Behavior?

J Clin Oncol; ePub 2016 Dec 12; Gray, et al

Most people who received elevated single nucleotide polymorphism-based cancer risk results from personal genomic testing kits did not make significant behavior changes, according to survey results from 762 respondents.

New kit purchasers took the survey, and investigators linked their answers to individual results. Among the findings:

  • ~One-fourth of individuals received elevated single nucleotide polymorphism-based cancer risk estimates for colorectal cancer.
  • The same was true for prostate cancer, and 12% received such for breast cancer.
  • At 6 months, customers who received elevated results were no more likely than those at average/reduced risk to change diet, exercise, or advanced planning behaviors, or engage in cancer screening.
  • 22% of men who received elevated prostate cancer risk estimates changed their vitamin and supplement use, vs 8% of those at average/reduced risk.
  • Baseline behavior, worsening health, and older age were predictors of 6-month behavior.
Citation:

Gray S, Gollust S, Carere D, et al. Personal genomic testing for cancer risk: results from the impact of personal genomics study. [Published online ahead of print December 12, 2016]. J Clin Oncol. doi:10.1200/JCO.2016.67.1503.

This Week's Must Reads

Survival as a Quality Metric of Cancer Care, J Oncol Pract; ePub 2017 Nov 1; Shulman, et al

Prostate Ca Outcomes by Insurance Type Assessed, Cancer; ePub 2017 Oct 30; Mahal, Mahal, et al

Impact of Insurance Type on Head and Neck Cancer, Cancer; ePub 2017 Nov 7; Gupta, Sonis, et al

Care Transitions in Patients with Advanced Cancer, J Clin Oncol; ePub 2017 Oct 25; Lage, et al

Racial and Ethnic Disparities in Cancer Survival, J Clin Oncol; ePub 2017 Oct 16; Ellis, et al

Must Reads in Preventive Care

Cochrane on Corticosteroids for Nausea, Vomiting, Cochrane; 2017 Jul 3; Vayne-Bossert, et al

Cochrane Evaluates Efficacy of Cancer Pain Meds, Cochrane; 2017 Jul 6; Wiffen, et al/Jul 12; Derry, et al/Jul 12; Wiffen, et al

Do Genomic Testing Cancer Risk Results Alter Behavior?, J Clin Oncol; ePub 2016 Dec 12; Gray, et al